Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atrasentan in Pediatric Patients With Primary IgA Nephropathy (Japan, Phase III, Single-arm)
jRCT2041260035Phase 3Recruiting
- Sponsor
- Novartis
- Start
- Aug 2026
- Modality
- Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of atrasentan in IgA nephropathy (IgAN), sponsored by Novartis. Primary endpoint: Change From Baseline in Proteinuria at Week 36. Started Aug 2026; status: recruiting.
02
Drugs
atrasentan
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on jRCT2041260035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041260035.